PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-41.39%
G&A reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
15.06%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
-38.60%
Operating expenses reduction while AXSM shows 6.62% growth. Joel Greenblatt would examine advantage.
-38.60%
Total costs reduction while AXSM shows 8.31% growth. Joel Greenblatt would examine advantage.
10.73%
Interest expense growth less than half of AXSM's 24.56%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
38.60%
Similar EBITDA growth to AXSM's 35.57%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
38.60%
Similar operating income growth to AXSM's 35.57%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
-122.72%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.20%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
30.20%
Net income growth exceeding 1.5x AXSM's 19.26%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
30.24%
EPS growth 1.25-1.5x AXSM's 20.49%. Bruce Berkowitz would examine sustainability.
30.24%
Diluted EPS growth 1.25-1.5x AXSM's 20.49%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.